Schroder Venture Life Sciences (SVLS) has expanded its investment team with the appointment of three new venture partners. Professor Graham Boulnois joins the London team and John Borzilleri and Dr Jeffrey Vender will be based in Boston.
Professor Boulnois joins from Aventis Pharma AG where he was senior vice president in drug innovation and approval. He has over 20 years experience in life sciences. At Aventis he had global responsibility for lead generation covering functional genomics, lead discovery technologies, medicinal and synthetic chemistry, chemical development and informatics. Prior to joining Aventis he spent a number of years at Zeneca Pharmaceuticals, latterly as senior vice president of discovery and then at AstraZeneca Pharmaceuticals as global vice president and head of enabling science and technology.
Dr Borzilleri has over 16 years experience in healthcare, most recently as senior vice president of equity research at State Street research and management, where he has led the healthcare team since 1997. Prior to this he was a practicing doctor. He will focus on advising investment opportunities for International Biotechnology Trust (IBT) plc, the UK quoted investment trust advised by Schroder Ventures Life Sciences.
Dr Vender will focus on opportunities in medical products and devices. He is a practicing anesthetist/critical care physician and a Professor of Anesthesia at Northwestern University, Chicago, as well as Chief of Anesthesia at Evanston Medical Centre, Evanston, Illinois, and has over 20 years experience in the medical world.
SVLS was established in 1994, as the dedicated life sciences arm of Schroder Ventures. Today it has 23 dedicated professionals in London and Boston who advise funds of over $500 million.